Chukwuka Akamnonu, MD
Endocrinology, Diabetes & Metabolism · Redlands, CANPI 1225423353
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,974, more than ten times the $157 reported in 2019.
Across 127 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$374
- Tandem Diabetes Care, Inc.$237
- Boehringer Ingelheim$227
- Medtronic$222
- Mannkind Corporation$178
- Insulet Corporation$175
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,851100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $374 |
| Tandem Diabetes Care, Inc. | 10 | $237 |
| Boehringer Ingelheim | 11 | $227 |
| Medtronic(2 entities) | 6 | $222 |
| Mannkind Corporation | 9 | $178 |
| Insulet Corporation | 9 | $175 |
| Xeris Pharmaceuticals, Inc. | 6 | $110 |
| Ascendis Pharma Endocrinology Inc | 4 | $99 |
| Abbott | 4 | $89 |
| Novartis | 3 | $87 |
| Lilly USA, LLC | 4 | $84 |
| Sequel Med Tech, LLC | 3 | $83 |
| Amgen | 4 | $78 |
| AstraZeneca | 3 | $61 |
| Madrigal Pharmaceuticals | 2 | $60 |
| Corcept Therapeutics | 2 | $57 |
| Acella Pharmaceuticals, LLC | 3 | $55 |
| BETA Bionics, Inc. | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $48 |
| United Therapeutics Corporation | 2 | $46 |
| Dexcom, Inc. | 3 | $45 |
| Rhythm Pharmaceuticals, Inc. | 2 | $41 |
| Neurocrine Biosciences, Inc. | 1 | $39 |
| AbbVie | 2 | $38 |
| Globus Medical | 1 | $37 |
| Ionis Pharmaceuticals, Inc. | 1 | $34 |
| Bayer | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Chiesi USA, Inc. | 1 | $27 |
| Amphastar Pharmaceuticals, Inc. | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| RGH Enterprises LLC | 1 | $19 |
| Cequr Corporation | 1 | $14 |
| GSK | 1 | $14 |
How this compares
$2,851 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 143 | $239,958 |
| OzempicSemaglutide | 182 | $182,790 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 40 | $94,211 |
| MounjaroTirzepatide | 62 | $65,551 |
| TrulicityDulaglutide | 43 | $48,687 |
| Teriparatide | 16 | $33,810 |
| HumatropeSomatropin | 16 | $30,902 |
| JardianceEmpagliflozin | 31 | $25,166 |
| JanuviaSitagliptin Phosphate | 16 | $13,441 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $12,848 |
| Repatha SyringeEvolocumab | 15 | $8,197 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,073 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $6,650 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $6,638 |
| Levothyroxine Sodium | 401 | $6,332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia, Evenity (2 Syringes) | $78 | $334,168183 claims |
| Novo NordiskOzempic | $374 | $182,790182 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humatrope, Insulin Lispro | $84 | $147,341141 claims |
| Boehringer IngelheimJardiance, Glyxambi | $227 | $31,80443 claims |
| AbbVieSynthroid, Armour Thyroid | $38 | $8,794132 claims |
| Sanofi-aventis U.S. LLCLantus | $29 | $1,81313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Redlands
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.